Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.
about
C3d fragment of complement interacts with laminin and binds to basement membranes of glomerulus and trophoblastTherapeutic implications of autoantibodies in rheumatoid arthritisIntra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis; correlation with clinical featuresLack of hidden complement fixing IgM rheumatoid factor in adult seronegative rheumatoid arthritis.Cellular phagocytic studies in rheumatoid arthritis patients treated with levamisoleSubnormal sensitivity of neutrophils to complement split product C5a in rheumatoid arthritis: relation to complement catabolism and disease extent.Isolation and analysis of complement activating aggregates from synovial fluid of patients with rheumatoid arthritis using monoclonal anti-C3d antibodies.Immunopathological abnormalities in the normal skin of patients with rheumatoid arthritis in relation to clinical and serological findings: a one year follow up study.Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy.Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase.Relative contribution of contact and complement activation to inflammatory reactions in arthritic jointsMonoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis.Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trialsImmune complexes in human diseases: a reviewInflammatory biomarkers in osteoarthritis.Immunonephelometric quantitation of complement split product (C3d) plasma levels in rheumatic disease.Essential role of surface-bound complement factor H in controlling immune complex-induced arthritisDetection of immune complexes in acute rheumatic fever and their relationship to HLA-B5.Familial rheumatoid arthritis: linkage of HLA to disease susceptibility locus in four families where proband presented with juvenile rheumatoid arthritisCirculating immune complexes in sera of children with neuroblastoma: correlation with stage of disease.Proteinaceous inhibitors of phospholipase A2 purified from inflammatory sites in ratsSoluble immune complexes in human disease.Circulating immune complexes in Lyme arthritis. Detection by the 125I-C1q binding, C1q solid phase, and Raji cell assaysThe use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.Differences in immunochemical characteristics of cryoglobulins in rheumatoid arthritis and systemic lupus erythematosus and their complement binding properties.Serum immune complexes containing IgA appear to predict erosive arthritis in a longitudinal study in rheumatoid arthritisLeucocyte complement receptor 1 (CR1/CD35) transcript and its correlation with the clinical disease activity in rheumatoid arthritis patients.Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis.
P2860
Q24680329-1307DC31-CE23-4848-A5E1-1266746F4D20Q26744033-91E13D9E-A2E3-4475-8464-6AC41F5C0C2DQ33551716-B6F9450D-A34D-470A-A15D-798ADFCCDA61Q33552338-7036123F-0C29-41E8-82BA-7B90AB2B6698Q33553055-7BB9DB24-4E5C-45BD-A471-0D25DAE5C5B6Q33556024-23FF4942-14F6-4FDC-9423-C1B48458333CQ33557184-936D5F03-2EDA-4D04-8CDA-C5FFC442BA2AQ33557315-F5BAF055-7143-46ED-B06E-0D108375A36EQ33560741-99E09B16-1998-4A58-B241-8E6CD1EB5431Q33561580-7D28F6FE-6F86-4FC4-9A97-4DAF4819A9F7Q33563013-2C367FC7-F590-436B-B00E-CDF88CDA86AAQ33584030-30F0E464-CA17-45A1-83F7-1ACDC55AB19BQ34558907-2249C2B5-827B-415D-A7F9-C8CBB7DC1835Q34681820-502935A0-6C70-4297-B081-D928264FE3D5Q35555743-938F3010-F152-4958-8348-3FCB059F3E9BQ35755442-4F387BC0-5FC4-4B31-ADCF-90294EBEBDB3Q35863255-FD454186-904D-49E4-94BC-188C5AEB7D3EQ36242268-2952A5D8-FE63-4D8D-BFE0-824EA1358BB2Q36487900-A072DE7C-F032-411C-B469-8431124CA04EQ36714001-710C061D-FB03-4649-8625-4BD4D6A3A97DQ37019408-568E18C5-C8A1-4AD1-8E86-2F9D3BE35E59Q37021256-0E9BBEEC-098F-4FE9-92DC-F764A4AA6E51Q37033835-DA4D5B56-8831-4FF0-B61E-3242DC6077D4Q37725005-701FA5BF-90C7-4BAC-92F0-F615623CB61CQ40217274-58BD831C-C5D3-4666-96B6-C63B09BE79A6Q40689281-BA777001-4BDF-41E2-A95D-1B96A0F976CAQ41139397-F3F1263A-17B1-457F-AD4D-A8100C3ECCAFQ41140471-D2EC9E75-336B-4C2C-991C-372DE3FED750Q41156232-DF12E61C-B7B5-4625-8C54-283AA041699DQ44237627-845E9362-8881-4261-AB11-4661A2DCD7D7Q55059596-96CA0325-1A1D-4771-8B4F-9A4B6A3D1B75
P2860
Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1977
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Circulating complement breakdo ...... plexes, and clinical activity.
@en
Circulating complement breakdo ...... plexes, and clinical activity.
@nl
type
label
Circulating complement breakdo ...... plexes, and clinical activity.
@en
Circulating complement breakdo ...... plexes, and clinical activity.
@nl
prefLabel
Circulating complement breakdo ...... plexes, and clinical activity.
@en
Circulating complement breakdo ...... plexes, and clinical activity.
@nl
P2093
P2860
P356
P1476
Circulating complement breakdo ...... plexes, and clinical activity.
@en
P2093
Karagevrekis CH
Lambert PH
Miescher PA
Nydegger UE
P2860
P304
P356
10.1172/JCI108708
P407
P577
1977-05-01T00:00:00Z